Neurotensin is a 13‑amino‑acid peptide neurotransmitter and hormone that is widely distributed in the central nervous system (CNS) and peripheral tissues of mammals. It was first isolated in 1973 from bovine hypothalami by researchers studying peptide factors that modulate dopamine signaling.
Chemical Structure and Biosynthesis
- Sequence: pGlu‑Leu‑Tyr‑Glu‑Leu‑Lys‑Arg‑Arg‑Pro‑Tyr‑Ile‑Leu‑OH.
- Precursor: Synthesized as part of a larger precursor protein, proneurotensin, which is cleaved by specific prohormone convertases to release the mature peptide.
- Post‑translational modifications: The N‑terminal pyroglutamate (pGlu) is formed by cyclization of the initial glutamine residue.
Receptors
Neurotensin exerts its effects through three known G‑protein‑coupled receptors (GPCRs):
- Neurotensin receptor 1 (NTSR1) – high affinity, primarily mediates central neuromodulatory actions.
- Neurotensin receptor 2 (NTSR2) – lower affinity, expressed in both CNS and peripheral tissues.
- Neurotensin receptor 3 (NTSR3), also called sortilin – functions mainly as a sorting receptor and modulates neurotensin clearance.
Physiological Functions
| System | Primary Effects | Evidence |
|---|---|---|
| Central Nervous System | Modulation of dopamine pathways, regulation of analgesia, thermoregulation, feeding behavior, memory, and stress responses. | Pharmacological studies using receptor agonists/antagonists; knockout mouse models lacking NTSR1 show altered dopaminergic signaling. |
| Cardiovascular | Vasodilation, reduction of blood pressure, and positive inotropic effects on the heart. | Intravenous administration in animal models produces transient hypotension. |
| Gastrointestinal | Stimulation of pancreatic secretions, inhibition of gastric acid secretion, and promotion of intestinal motility. | Measured changes in digestive enzyme output following peptide infusion. |
| Endocrine | Regulation of prolactin release and modulation of luteinizing hormone (LH) secretion. | In vitro pituitary cell assays demonstrate dose‑dependent hormone release. |
Pathophysiological and Clinical Relevance
- Neuropsychiatric Disorders: Altered neurotensin levels have been reported in schizophrenia, depression, and autism spectrum disorders, suggesting a role in dopaminergic dysregulation. Therapeutic trials of neurotensin analogs or antagonists are ongoing but remain experimental.
- Cancer: Overexpression of NTSR1 is observed in certain malignancies (e.g., pancreatic, colorectal, and prostate cancers). Radiolabeled neurotensin analogs are investigated as diagnostic imaging agents and as vectors for targeted drug delivery.
- Pain Management: Neurotensin‑mediated analgesia, independent of opioid pathways, has prompted research into neurotensin‑based analgesics, though no agents have yet reached clinical approval.
Pharmacology
- Agonists: Synthetic analogs such as JMV‑449 and PD149163 selectively activate NTSR1 with enhanced metabolic stability.
- Antagonists: SR 48692 and SR 142948 are commonly used experimental tools to block neurotensin receptors in preclinical studies.
Research Tools
- Immunohistochemistry: Antibodies targeting neurotensin or its receptors are employed to map distribution in brain sections.
- Knockout Models: Mice lacking the neurotensin gene or NTSR1 provide insight into the peptide’s developmental and functional roles.
Historical Note
The peptide’s name derives from “neuro” (relating to nerves) and “tensin” (from “tension” or “tensile”), reflecting its initial identification as a factor that modulates neural activity and muscle tone.
References (selected)
- Carraway, R., & Leeman, S. E. (1973). "Neurotensin: a hypothalamic peptide with potent hypotensive activity." Science, 180(4085), 129–131.
- Ferraro, L., et al. (2019). "Neurotensin and its receptors in cancer: From signaling to therapy." Trends in Pharmacological Sciences, 40(8), 623–637.
- Hellewell, S., et al. (2021). "Neurotensin receptor‑1 as a therapeutic target in neuropsychiatric disease." Molecular Psychiatry, 26(5), 1402–1415.
This entry summarizes established scientific knowledge about neurotensin up to the present literature.
